BioNTech SE (BNTX)
| Market Cap | 27.34B |
| Revenue (ttm) | 2.97B |
| Net Income (ttm) | -827.93M |
| Shares Out | 246.24M |
| EPS (ttm) | -3.45 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 441,493 |
| Open | 111.20 |
| Previous Close | 112.89 |
| Day's Range | 110.00 - 111.53 |
| 52-Week Range | 76.53 - 131.49 |
| Beta | 1.30 |
| Analysts | Strong Buy |
| Price Target | 141.60 (+27.53%) |
| Earnings Date | Aug 4, 2025 |
About BNTX
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph... [Read more]
Analyst Summary
According to 18 analysts, the average rating for BNTX stock is "Strong Buy." The 12-month stock price target is $141.6, which is an increase of 27.53% from the latest price.
News
Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win
Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents, in the latest round of a long-run...
5 Stocks To Ride The German Market Rally
Stocks in the United States have struggled to regain their February all-time highs amid the tariff uncertainty. In fact, the S&P 500 remains one of the worst-performing major stock indices in the deve...
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
BioNTech SE BNTX on Thursday agreed to acquire CureVac N.V. CVAC in an all-stock transaction.
BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.
CureVac stock soared 29% $5.26 in premarket trading immediately following the news.
BioNTech to acquire CureVac in $1.25 billion all-stock deal
German biotech firm BioNTech said on Thursday it agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares to boost its work on new mRNA-based cancer treatments.
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
MAINZ and TÜBINGEN, Germany, June 12, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into a definitiv...
RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts say
Health and Human Services Secretary Robert F. Kennedy Jr. has gutted a key government panel of vaccine advisors, a stunning move that some public health experts say undermines science, disrupts a trus...
Vaccine actions and policy positions under US Health Secretary Kennedy
U.S. Health Secretary Robert F. Kennedy Jr., a long-time vaccine skeptic, has been making sweeping changes to reshape U.S. regulation of vaccines, food and medicine.
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up
Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccin...
Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.
Investors will be waiting for news on how the makeup of a reconstituted ACIP will look like.
Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment
Bristol-Myers Squibb is attractively valued, offers a 5%+ dividend yield, and benefits from a strong oncology pipeline after its BioNTech deal. The $11B BioNTech partnership gives BMY access to BNT327...
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.
Bristol Myers CEO explains why he's spending billions on BioNTech deal
Bristol-Myers Squibb Co (NYSE: BMY) is inching up on Monday after announcing an $11 billion deal with BioNTech SE (Nasdaq: BNTX) aimed at transforming cancer treatment. The pharmaceutical behemoth ann...
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.
Bristol Myers Squibb CEO on $11B cancer drug deal with BioNTech
Christopher Boerner, CEO of Bristol Myers Squibb, said Monday that the company's $11 billion cancer drug partnership with BioNTech could be "the next new frontier in the treatment of cancer." The comp...
Bristol Myers CEO on Biontech deal: Next new frontier in treatment of cancer
Christopher Boerner, Bristol Myers CEO, joins 'Squawk on the Street' to discuss the company's recent partnership with Biontech, the cost of the deal and much more.
Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race
Shares of BioNTech SE were soaring in early Monday trading, after Bristol Myers Squibb Co. made an $11.1 billion splash in the rapidly growing new cancer-drug game.
BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb
BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech's BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.
Bristol Myers to pay $1.5 billion upfront for BioNTech cancer drug partnership
U.S. drugmaker Bristol Myers Squibb announced on Monday a $1.5 billion upfront payment to partner with Germany's BioNTech , on an experimental cancer drug, in a deal that could eventually exceed $11 b...
BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting
MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data from select pipeline candidates across the Company's diversified oncology portf...
BioNTech plans up to $1.33 billion investment in the United Kingdom
German vaccine maker BioNTech said on Tuesday that it plans to invest up to 1 billion pounds ($1.33 billion) over the next ten years to broaden its research and development activities in the United Ki...
New vaccine chief rocks pharmaceutical stocks
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.
BioNTech: mRNA Challenges Amid Regulatory Uncertainty (Rating Downgrade)
BioNTech maintains strong cash reserves (€15.85B) despite widening losses as COVID revenues decline and R&D expenses increase. BNT327 (PD-L1/VEGF-A bispecific) advances to Phase 3 trials, but shares d...
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion
BioNTech SE BNTX on Monday reported a first-quarter per-share loss of $1.82 (1.73 euros), up from 1.31 euros reported a year ago compared to beating the consensus of $2.02.
BioNTech SE (BNTX) Q1 2025 Earnings Call Transcript
BioNTech SE (NASDAQ:BNTX) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Co-Founder & Chief Executive Office...